Scarica l'app Stockscreener
0.5754
4.10%
-0.0246
Precedente Chiudi:
$0.60
Aprire:
$0.6
Volume 24 ore:
757.37K
Relative Volume:
1.05
Capitalizzazione di mercato:
$53.10M
Reddito:
$2.24M
Utile/perdita netta:
$-136.67M
Rapporto P/E:
-0.2513
EPS:
-2.29
Flusso di cassa netto:
$-102.08M
1 W Prestazione:
-6.64%
1M Prestazione:
+9.39%
6M Prestazione:
-52.84%
1 anno Prestazione:
-82.35%
Intervallo 1D:
$0.5621
$0.6087
Intervallo di 1 settimana:
$0.5621
$0.655
Portata 52W:
$0.3418
$3.30
Century Therapeutics Inc Stock (IPSC) Company Profile
Nome
Century Therapeutics Inc
Settore
Industria
Telefono
215-981-4000
Indirizzo
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Confronta IPSC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5754 | 53.10M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-08 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Iniziato | Chardan Capital Markets | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-05-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-12 | Iniziato | William Blair | Mkt Perform |
| 2021-07-13 | Iniziato | BofA Securities | Buy |
| 2021-07-13 | Iniziato | JP Morgan | Overweight |
| 2021-07-13 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
66,797 Shares in Century Therapeutics, Inc. (NASDAQ:IPSC) Acquired by Two Sigma Investments LP - Defense World
Jane Street Group LLC Increases Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Acquired by Squarepoint Ops LLC - Defense World
Two Sigma Advisers LP Takes $52,000 Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Nuveen Asset Management LLC Raises Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - sharewise
Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress - MSN
Deutsche Bank AG Purchases 173,849 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Millennium Management LLC Grows Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Q2 EPS Estimate for Century Therapeutics Raised by Analyst - Defense World
Brokers Issue Forecasts for IPSC Q1 Earnings - Defense World
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress - GlobeNewswire
Chardan Capital Issues Optimistic Forecast for IPSC Earnings - Defense World
Leerink Partnrs Has Negative Forecast for IPSC Q2 Earnings - Defense World
Century Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline - MSN
Chardan Trims Price Target on Century Therapeutics to $6 From $7, Maintains Buy Rating - marketscreener.com
Chardan Capital Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $6.00 - Defense World
Chardan Capital Lowers Price Target for Century Therapeutics (IP - GuruFocus
Chardan Capital Lowers Price Target for Century Therapeutics (IPSC) | IPSC Stock News - GuruFocus
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates - sharewise
Century Therapeutics Expands iPSC Cell Therapy to Europe as Q1 Revenue Surges to $109M - Stock Titan
Marshall Wace LLP Purchases New Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Buys 91,468 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
A closer look at Century Therapeutics Inc (IPSC)’s stock price trends - uspostnews.com
Geode Capital Management LLC Acquires 23,413 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting - MSN
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Century Therapeutics (IPSC) Expected to Announce Earnings on Thursday - Defense World
An Analysis of Century Therapeutics Inc (IPSC)’s Potential Price Growth - knoxdaily.com
Renaissance Technologies LLC Boosts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Market Insight: Century Therapeutics Inc (IPSC)’s Notable Drop, Closing at 0.50 - DWinneX
Century Therapeutics to Present Preclinical Data at ASGCT 28th Annual Meeting on Novel iPSC-Derived Cell Therapies for Autoimmune Diseases and Cancer - Nasdaq
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting - GlobeNewswire
Century Therapeutics Reveals Groundbreaking Cancer-Fighting Cell Therapy Data at Major Scientific Conference - Stock Titan
IPSCCentury Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Is it possible to buy Century Therapeutics Inc(IPSC) shares at a good price now? - uspostnews.com
Century Therapeutics Inc (IPSC): A Sitting Duck With -825.93% Upside Potential - Stocksregister
H.C. Wainwright maintains Buy rating on Century Therapeutics stock - Investing.com
Century Therapeutics Inc (IPSC)’s financial ratios: A comprehensive overview - DWinneX
H.C. Wainwright maintains Buy rating on Century Therapeutics stock By Investing.com - Investing.com UK
Century Therapeutics Inc [IPSC] Stock sold by Insider Pfeiffenberger Brent for $1375.0 - knoxdaily.com
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MSN
Century Therapeutics to Host Live Chat on Preclinical Cell Therapy Programs Targeting Autoimmune Diseases and Cancer - Nasdaq
Century Therapeutics to Host Live Fireside Chat Focused on - GlobeNewswire
Century Therapeutics Unveils Next-Gen Cell Therapy Pipeline for Cancer and Autoimmune | IPSC Stock News - Stock Titan
American Century Companies Inc. Buys Shares of 105,337 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Century Therapeutics Inc Azioni (IPSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Century Therapeutics Inc Azioni (IPSC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farid Adrienne | Chief Operations Officer |
Jun 09 '25 |
Sale |
0.62 |
552 |
343 |
250,141 |
| Pfeiffenberger Brent | President and CEO |
Jun 09 '25 |
Sale |
0.62 |
475 |
295 |
1,681,783 |
| Russotti Gregory | See Remarks |
Jun 09 '25 |
Sale |
0.62 |
526 |
327 |
392,047 |
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):